基石药业-B：CS2009（PD-1/VEGF/CTLA-4三特异性抗体）Ⅱ期临床试验联合疗法IND在中国获批

Core Viewpoint - The company announced the approval of its clinical trial application for CS2009, a novel tri-specific antibody targeting PD-1, VEGFA, and CTLA-4, for use in late-stage solid tumors by the National Medical Products Administration (NMPA) of China [1] Group 1 - CS2009 is developed independently by the company from molecular design [1] - The tri-specific antibody aims to achieve multi-dimensional anti-tumor effects through synergistic action [1]